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1457category [male or female]) score (i.e., myocardial infarction, com-
plex aortic plaque, and PAD), advocated by the European Society of
Cardiology guidelines on the management of atrial fibrillation, to
assess the risk of stroke (3). However, we think that prior to pro-
posing the measurement of ABI in patients with nonvalvular atrial
fibrillation, several issues should be discussed.
First, the main interest of the CHADS2-VASc score is to
determine whether oral anticoagulant therapy (OAC) is necessary.
The European Society of Cardiology guidelines recommend OAC
when CHADS2-VASc is 2 and prefer OAC to aspirin when the
score is 1 (3). Hence, the practical interest of ABI measurement
would be limited to those with a CHADS2-VASc score of 0 or 1 in
order to detect “missed” cases of PAD, which would lead to
increasing the score by 1 point and ultimately to revising the
anticoagulation strategy. In their study, Violi et al. (1) report high
rates of diabetes, hypertension, and history of myocardial infarction
or stroke among those with an ABI 0.90. All those variables lead
to a higher CHADS2-VASc score, so that the prevalence of
ABI 0.90 among those with a current CHADS2-VASc score at
0 or 1 should be reported to clarify its incremental value to change
anticoagulation strategy in these low-risk patients.
Second, 10% of the study population had anABI>1.40, and these
patients have apparently not been adequately taken into consider-
ation, because almost one-half of these patients do have underlying
PAD, although the definite diagnosis would need further tests as the
ABI measurement is impeded by calcified arteries (4).
Finally, the accuracy of the ABI measurement in case of irregular
rhythm is unknown. It has been shown that the measurement of
arm blood pressure in this situation is associated with considerable
intra- and interobserver variability, and it is plausible to wonder at
similar poor results when making the ratio of pressures measured in
several limbs (5). The only way to moderate the level of inaccuracy
is to advocate systematically repeated measurements and to avoid
taking the crucial decision of OAC on the basis of a sole mea-
surement of the ABI.
Once these issues are addressed, we agree with Violi et al. that a
prospective study is necessary to assess the ability of the ABI to
reclassify low-risk patients and increase the CHADS2-VASc score
discrimination index to predict stroke events in case of nonvalvular
atrial fibrillation. Ultimately, a trial would be necessary to clarify the
interest of OAC in patients with both low CHADS2-VASc score
and ABI.*Victor Aboyans, MD, PhD
Philippe Lacroix, MD
Najmeddine Echahidi, MD
Dania Mohty, MD, PhD
*Department of Cardiology
Dupuytren University Hospital
2 Martin Luther King Avenue
Limoges 87042
France
E-mail: vaboyans@live.fr
http://dx.doi.org/10.1016/j.jacc.2013.09.071REFERENCES
1. Violi F, Davi G, Hiatt W, et al. Prevalence of peripheral artery disease by
abnormal ankle-brachial index in atrial fibrillation: implications for risk
and therapy. J Am Coll Cardiol 2013;62:2255–6.2. Fan H, Hu X, Yu W, et al. Low ankle-brachial index and risk of stroke.
Atherosclerosis 2013;229:317–23.
3. European Heart Rhythm Association, European Association for Cardio-
Thoracic Surgery, Camm AJ, et al. Guidelines for the management of
atrial fibrillation: the Task Force for the Management of Atrial Fibril-
lation of the European Society of Cardiology (ESC). Eur Heart J 2010;
31:2369–429.
4. Aboyans V, Criqui MH, Abraham P, et al. Measurement and inter-
pretation of the ankle-brachial index: a scientific statement from the
American Heart Association. Circulation 2012;126:2890–909.
5. Sykes D, Dewar R, Mohanaruban K, et al. Measuring blood pressure in
the elderly: does atrial fibrillation increase observer variability? BMJ
1990;300:162–3.ReplyAnkle-Brachial Index in
Patients With Nonvalvular
Atrial Fibrillation
We thank Dr. Aboyans and colleagues for their comments on our
paper (1) in which we reported a 21% prevalence of low (0.90)
ankle-brachial index (ABI) in a population suffering from non-
valvular atrial fibrillation. The inclusion of low ABI in the defi-
nition of vascular disease within the CHA2DS2-VASc (congestive
heart failure [or left ventricular systolic dysfunction]; hypertension
[blood pressure consistently >140/90 mm Hg or on hypertension
medication]; age 75 years; diabetes mellitus; previous stroke,
transient ischemic attack, or thromboembolism; vascular disease
[e.g., peripheral artery disease, myocardial infarction, aortic pla-
que]; age 65 to 74 years; sex category [i.e., female]) score sub-
stantially modified the prevalence of vascular disease, which
increased from 17.3% to 33%. This had a particular impact on the
CHA2DS2-VASc score subclasses between 0 and 1, whereby the
inclusion of a low ABI in the score resulted in a potential risk
upgrading.
Thus, 9.5% of patients in classes 0 and 1 had a low ABI; of these,
20% and 80% were CHA2DS2-VASc classes 0 and 1, respectively.
Among patients classified as CHA2DS2-VASc score 0, smoking
was the only risk factor in 29% of patients; among those classified
as CHA2DS2-VASc score 1, 43 (18%) were women, 34 (14%) aged
from 65 to 74 years, 149 (63%) were hypertensive, 5 (2%) were
diabetic, and 6 (3%) had vascular components of the “classic”
CHA2DS2-VASc score.
The presence of an ABI 1.40 can be detected in atherosclerotic
patients, particularly in those with diabetes and this usually reflects
tibial artery calcification and is a predictor of cardiovascular disease
and total mortality (2). An ABI 1.40 was detected in 10% of our
nonvalvular atrial fibrillation patients. When patients with
ABI 1.40 were compared with those with ABI >0.90 to 1.39
(Table 1), we found that women were more prevalent in the group
of patients with normal ABI; conversely arterial hypertension and
diabetes mellitus were more frequent in patients with ABI 1.40.
Although the definite diagnosis of PAD would need further tests
as the ABI measurement is confounded by calcified arteries, we will
consider the possibility to evaluate the predictive power of this
parameter in future survival analyses.
We planned this study in 2010 using the Doppler method
for the determination of the ABI and organized a training
meeting to reduce inaccuracy level. Training included demon-
stration of performance of an ABI in nonvalvular atrial
Table 1
Clinical Characteristics and Pharmacologic Treatments Ac-
cording to ABI Ranging From 0.91 to 1.39 and 1.40
ABI 0.91–1.39
(n ¼ 1,381) p Value
ABI 1.40
(n ¼ 204)
Age 65–74 yrs 347 (25) NS 41 (20)
Age 75 yrs 603 (44) 94 (46)
Female 642 (47) <0.002 71 (35)
Paroxysmal NVAF 600 (44) NS 87 (42)
Persistent NVAF 196 (14) 26 (13)
Permanent NVAF 585 (42) 91 (45)
AH 1,115 (81) <0.04 177 (87)
Diabetes 265 (19) <0.03 53 (26)
Smoking habit 194 (14) NS 19 (9)
Previous TIA/stroke 136 (10) NS 21 (10)
Vascular disease 215 (16) NS 26 (13)
CHA2DS2-VASc*
0 66 (5) NS 7 (4)
1 181 (13) 31 (15)
 2 1,134 (82) 166 (81)
Antithrombotic NS
None 217 (16) 30 (15)
OAC 836 (60) 138 (67)
APs 270 (20) 28 (14)
OAC þ APs 58 (4) 8 (4)
Statins 496 (36) NS 62 (31)
Oral hypoglycemic agents 166 (12) NS 35 (17)
Values are n (%). *Vascular disease includes previous myocardial infarction, peripheral arterial
disease, or aortic plaque.
ABI ¼ ankle-brachial index; AH ¼ arterial hypertension; APs ¼ antiplatelet drugs; NVAF ¼ non-
valvular atrial fibrillation; OAC ¼ oral anticoagulants; TIA ¼ transient ischemic attack; CHA2DS2-
VASc ¼ congestive heart failure [or left ventricular systolic dysfunction]; hypertension [blood
pressure consistently >140/90 mm Hg or on hypertension medication]; age 75 years; diabetes
mellitus; previous stroke, transient ischemic attack, or thromboembolism; vascular disease [e.g.,
peripheral artery disease, myocardial infarction, aortic plaque]; age 65 to 74 years; sex category
[i.e., female]).
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1458fibrillation patients with clear delineation of each step. In
addition, the follow-up study required a repeat measurement of
ABI every 12 months.
We agree with Dr. Aboyans and colleagues that our findings
are particularly relevant in patients classified as CHA2DS2-VASc
score 0 and 1 as the inclusion of low ABI may upgrade the risk
and eventually change the therapeutic approach in patients
considered at low-to-moderate risk. Inclusion of ABI 0.90 in
the CHA2DS2-VASc might have important therapeutic impli-
cations only if incorporation of ABI into the CHA2DS2-VASc
score is prospectively tested. Thus, the results of our ongoing
prospective study will validate this and clarify its incremental
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Plaque Erosion and
Calcified Nodules
“Seeing Is Believing”
Plaque erosion (PE) and calcified nodules (CN) have been classically
described in pathological studies as causes of acute coronary syn-
dromes (ACS) (1). However, until very recently, the diagnosis of
these entities in the clinical setting has remained largely elusive (1). In
this regard, the study of Jia et al. (2), using optical coherence to-
mography (OCT) for the diagnosis of PE andCN, is ofmajor clinical
interest and raises several important issues. First, the investigators
considered that OCT might provide a “definitive” diagnosis of PE
when fibrous cap disruption is excluded and a thrombus overlying an
“intact” plaque is visualized. However, considering that OCT lacks
the resolution required to visualize mild superficial endothelial ero-
sions and that coronary thrombi may displace along the vessel (either
spontaneously or following instrumentation) and actually originate
from a remote source (3), we believe that these OCT findings should
be considered as diagnostic of “probable” PE. Likewise, lumen sur-
face irregularities without associated thrombus and plaque attenua-
tion by red thrombus (2) are probably better classified as “possible”
PE. In our experience, in some patients, a repeated OCT study after
several days of intense antithrombotic therapy may unravel the true
characteristics of the underlying plaque, once the overlying thrombus
has disappeared or drastically reduced in size (3). Indeed, in some of
these patients, a previously hidden small plaque rupturedrather than
an intact plaquedmay be eventually visualized. As this strategy may
help to better identify patients with PE, it will be of interest to know
if similar “evolving” findings were found in some patients in this
study. Second, until now, the value of OCT to detect CN has not
been established. Nevertheless, anecdotal patients presenting with
large “superficial” calcified plates and associated intracoronary
thrombosis have been recently reported (4,5). However, we believe
that visualization of a “rupture” should not be required for the
diagnosis of CN (2), although this finding might be critical in the
diagnosis of complicated CN. Notably, previous studies using virtual
histology have demonstrated that silent, uncomplicated, protruding
CN may be detected in nonculprit vessels of ACS patients and also
that the prognosis of these plaques is rather benign (6). Furthermore,
